Latest market price
165.36
+20.01+13.77%
NBIXQT59Neurocrine Biosciences, Inc.·NASDAQ
165.36+13.77%

Latest SEC Filings

Form category
DescriptionFilingDocument
Nov 02, 20268-KCurrent report
Nov 02, 202610-QQuarterly report
Oct 30, 2026SC 13GBeneficial ownership statement (passive)
Oct 15, 2026SC 13G/ABeneficial ownership statement (passive, amended)
Oct 07, 20263Initial statement of beneficial ownership
Sep 28, 20268-KCurrent report
Sep 15, 20264Statement of changes in beneficial ownership
Sep 15, 20264Statement of changes in beneficial ownership
Sep 15, 20264Statement of changes in beneficial ownership
Sep 15, 20264Statement of changes in beneficial ownership
Sep 15, 20264Statement of changes in beneficial ownership
Sep 15, 20264Statement of changes in beneficial ownership
Sep 15, 20264Statement of changes in beneficial ownership
Sep 15, 20264Statement of changes in beneficial ownership
Sep 15, 20264Statement of changes in beneficial ownership
Sep 15, 20264Statement of changes in beneficial ownership
Sep 10, 20264Statement of changes in beneficial ownership
Sep 03, 20264Statement of changes in beneficial ownership
Aug 05, 20264Statement of changes in beneficial ownership
Jul 31, 2026S-8Registration of employee benefit securities
Jul 31, 202610-QQuarterly report
Jul 31, 20268-K/ACurrent report (amended)
Jul 30, 20264Statement of changes in beneficial ownership
Jul 30, 20268-KCurrent report
Jul 27, 2026SC 13G/ABeneficial ownership statement (passive, amended)